A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
Principal Investigator: Marcel Hungs, MD, PhD
Study sponsor: Eli Lilly
Location: Center for Memory and Aging, Neuroscience Center
Phase of Study: III
Purpose of study: The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer’s disease occurring in participants receiving study drug compared to placebo.
Inclusion Criteria:
– Age 55-80
– Have at least 1 reliable study partner
– Have a plasma P-tau at first visit
Exclusion Criteria:
– Have dementia
– Cannot have an MRI
– Are enrolled in other medical research
Study Contact:
Meghan O’Brien
(651) 493-6363
ClinicalTrial@HealthPartners.com
